Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Trial ID or NCT#

NCT01206309

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

Official Title

Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Planned or completed first allogeneic stem cell transplant (any conditioning regimen, graft source, donor type and GVHD prophylaxis regimen) - Signed, informed consent and, if applicable, child assent
Exclusion Criteria:
  1. - Inability to comply with study procedures - Anticipated survival less than 6 months due to co-morbid disease - Autoimmune disorder or inherited immunodeficiency before HCT - Diagnosis of late acute or chronic GVHD prior to study enrollment - Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of HCT or at the time of enrollment (e.g., > 5% blasts for leukemia; poorly responsive lymphoma)
View All Criteria
Show Less

Investigator(s)

Sally Arai
Sally Arai
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Laura Johnston
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Medical oncologist, Hematologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

Physician Referrals
650-723-0822

View on ClinicalTrials.gov